Seo Geom Seog, Chae Soo-Cheon
Geom Seog Seo, Department of Gastroenterology, Wonkwang University School of Medicine, Digestive Disease Research Institute, Chonbuk 570-749, South Korea.
World J Gastroenterol. 2014 Oct 7;20(37):13234-8. doi: 10.3748/wjg.v20.i37.13234.
Of the diverse biological agents used for patients with ulcerative colitis, the anti-tumor necrosis factor-α agents infliximab and adalimumab have been used in large-scale clinical trials and are currently widely used in the treatment of inflammatory bowel disease patients. Recent studies have indicated that golimumab, oral tofacitinib and vedolizumab reportedly achieved good clinical response and remission rates in ulcerative colitis patients. Thus, we believe that the detailed investigation of various studies on clinical trials may provide important information for the selection of appropriate biological agents, and therefore, we have extensively reviewed such trials in the present study.
在用于溃疡性结肠炎患者的多种生物制剂中，抗肿瘤坏死因子-α制剂英夫利昔单抗和阿达木单抗已用于大规模临床试验，目前广泛用于治疗炎症性肠病患者。最近的研究表明，据报道戈利木单抗、口服托法替布和维多珠单抗在溃疡性结肠炎患者中取得了良好的临床反应和缓解率。因此，我们认为对各项临床试验研究进行详细调查可能为选择合适的生物制剂提供重要信息，因此，我们在本研究中对这类试验进行了广泛回顾。
